Pelthos Therapeutics to Present at 38th Annual ROTH Conference

About this update from Pelthos Therapeutics Inc.

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38 th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time. Investors interested in arranging one-on-one meetings should contact their ROTH representative. A live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company’s website at  https://pelthos.com . A replay of the webcast will be available for 90 days following the event. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum . The company’s portfolio of assets also includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at  www.pelthos.com . Follow Pelthos on  LinkedIn  and X . Contacts Investors: LifeSci Advisors, LLC Mike Moyer, Managing Director [email protected] Media: KWM Communications Kellie Walsh [email protected] (914) 315-6072

View stock analysis, news, and events for Pelthos Therapeutics Inc.